Animal models to guide clinical drug development in ADHD: lost in translation?

摘要: We review strategies for developing animal models examining and selecting compounds with potential therapeutic benefit in attention-deficit hyperactivity disorder (ADHD). ADHD is a behavioural of unknown aetiology pathophysiology. Current understanding suggests that genetic factors play an important role the ADHD. The involvement dopaminergic noradrenergic systems pathophysiology probable. clinical features including inattention, impulsivity how these are operationalized laboratory study. Measures temporal discounting (but not premature responding) appear to predict known drug effects well (treatment validity). Open-field measures overactivity commonly used do have treatment validity human populations. A number been proposed simulate symptoms most spontaneously hypertensive rat (SHR) 6-hydroxydopamine-lesioned (6-OHDA) animals. To date, however, SHR lacks validity, drugs on inattention studied extensively 6-OHDA-lesioned At present stage development, there no vivo proven effectiveness However, emerging theme theories ADHD, good evidence increased value delayed reward following stimulant drugs. Therefore, operant behaviour paradigms measure situations reinforcement, whether normal rats or selected models, show promise future. LINKED ARTICLES This article part themed issue Translational Neuropharmacology. view other articles this visit http://dx.doi.org/10.1111/bph.2011.164.issue-4